A Study of Thymic Humoral Factor (THF Gamma 2) in HIV-Infected Patients

Inclusion Criteria

• •Concurrent Medication:
• •Allowed:
• •AZT or another antiretroviral agent (marketed or investigational under a Treatment IND).
• •Primary prophylaxis for Pneumocystis carinii pneumonia (PCP), toxoplasmosis, and Mycobacterium avium-intracellulare (MAI) if patient's CD4 count decreases to \< 200 cells/mm3.
• •Other marketed drugs as required.
• •Patients must have:
• •HIV seropositivity and be either asymptomatic or have persistent generalized lymphadenopathy (PGL).
• •No history of symptoms in Category B or C of 1993 Case Definition, other than oral candidiasis following previous broad-spectrum antibiotic therapy.
• •Mean CD4 of 200-500 cells/mm3.
• •HIV-1 positive PCR RNA.
• •Ability to self-administer study drug by IM injection.
• •Ability to tolerate AZT at 600 mg daily during first 8 weeks of run-in period (if AZT naive) OR tolerated AZT at \>= 500 mg daily for at least 3 months but no more than 12 months prior to randomization.